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Genetics of Aplasia Cutis Reveal Novel Regulators of Skin
Morphogenesis
Alexander G. Marneros1
The molecular mechanisms that control skin morpho-
genesis are complex and only incompletely under-
stood. Aplasia cutis manifests with localized skin
defects at birth and is a feature in various syndromes.
Identifying the genes that cause these genetic skin
conditions provides the opportunity to define novel
regulators of skin morphogenesis. Recently, human
genetic approaches have led to the identification of
aplasia cutis–causing mutations in genes that have
previously not been implicated to have an important
role in skin biology. These findings reveal novel
molecular mechanisms that are involved in skin for-
mation during development.
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INTRODUCTION
The genetic basis of the various congenital disorders that
manifest with localized defects in skin formation has been
largely unknown. Identifying the genetic causes and patho-
mechanisms involved in these congenital disorders provides
the opportunity to gain fundamental new insights into mole-
cular pathways that are important for skin morphogenesis.
Thus, although these congenital skin disorders may not be
common, they are likely to provide very valuable insights into
basic mechanisms of skin biology. Examples of such disorders
include aplasia cutis congenita (ACC) and multiple genetic
syndromes that manifest also with localized skin defects in
addition to other congenital malformations. Examples of
congenital syndromes with a consistent manifestation of
ACC include scalp-ear-nipple (SEN) syndrome and Adams–
Oliver syndrome (AOS). Some of the genetic causes for
familial ACC, SEN syndrome, and AOS were recently identi-
fied, revealing mutated genes of which most have previously
not been recognized to have an important role in skin biology
(Table 1). Although these genes function in distinct molecular
pathways, the observed aplasia cutis lesions among these
syndromes are often clinically indistinguishable and show no
consistent characteristic differences. Notably, individuals with
congenital aplasia cutis lesions have not been reported to
show wound-healing defects or generalized skin abnormalities
in adulthood, suggesting that the pathomechanisms involved
affect developmental skin formation and can be fully com-
pensated for in the adult. Here, these identified genes are
reviewed and potential common pathomechanisms that lead
to the skin defects discussed.
AUTOSOMAL-DOMINANT ACC
ACC manifests with localized skin defects at birth,
most commonly affecting the scalp vertex, and heals with a
scar. Histologically, a complete absence of the epidermis and
skin appendages is observed at the site of ACC at birth,
suggesting a localized skin morphogenesis defect. ACC most
commonly presents as sporadic cases, although familial
occurrence has been reported (Evers et al., 1995). ACC is
frequently underreported, and some estimate its frequency to
be at 1:3,000 births. Although ACC occurs also in various
congenital syndromes that manifest with additional
abnormalities, ACC usually occurs without other congenital
abnormalities.
A mutation in the ribosomal GTPase BMS1 in autosomal-
dominant ACC
Recently, the causative gene mutation in a family with
autosomal-dominant ACC has been identified (Marneros,
2013). Notably, ACC was present only on the scalp, and the
severity of ACC was highly variable among affected family
members (Figure 1a). The congenital wounds healed with
either an atrophic or a hypertrophic scar. No other congenital
abnormalities were observed in this family. Genome-wide
linkage analysis and exome sequencing identified a hetero-
zygous missense mutation in the ribosomal GTPase BMS1 in
affected family members. BMS1 is required for proper forma-
tion of the 40S ribosomal subunit and depletion of BMS1
interferes with pre-ribosomal RNA processing at sites required
for generation of 18S ribosomal RNA (Gelperin et al., 2001;
Wegierski et al., 2001). BMS1 binds to the endonuclease Rcl1
in a guanosine triphosphate (GTP)-dependent manner and
is required to recruit Rcl1 to preribosomes and induce
maturation of the small ribosomal subunit (Karbstein et al.,
2005; Karbstein and Doudna, 2006).
Consistent with this function of BMS1, fibroblasts derived
from ACC patients with this BMS1 mutation showed a delay of
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maturation of the small ribosomal subunit, which resulted in a
nucleolar stress response and a p21-mediated G1/S phase
transition delay that led to a reduced cell proliferation rate
(Marneros, 2013). Global comparative proteomic and
transcriptional analyses of ACC skin fibroblasts with the
BMS1 mutation provided additional evidence for a central
role of p21 activation for the ACC phenotype (Marneros,
2013). Inducible knockdown of BMS1 in skin fibroblasts to
B50% of normal BMS1 levels showed a similar delay in
ribosomal small subunit maturation as in fibroblasts obtained
from a patient with ACC carrying the heterozygous BMS1
mutation, suggesting that this mutation results in a loss-of-
function BMS1 allele.
These data identified the first causative ACC gene mutation
and provided a novel link between BMS1 function, the cell
cycle, and skin morphogenesis. Furthermore, the findings
suggest an important role of ribosome biogenesis for proper
scalp skin formation. Future studies will determine how
frequently BMS1 is mutated in ACC and whether there is
genetic heterogeneity in non-syndromic ACC.
Hypotheses of how the BMS1 mutation may lead to ACC
For other diseases with abnormal ribosomal function
increased free ribosomal proteins have been shown to inacti-
vate Mdm2 for p53 digestion, and p53 accumulation induced
p21 transcription (Donati et al., 2012). This pathway explains
a p53-dependent nucleolar stress response and p21-mediated
cell cycle arrest in ribosomopathies. Alternatively, a p53-
independent pathway has been described, in which cell cycle
arrest occurs because of ribosomal stress. Here, abnormal
ribosomal processing or assembly leads to an increase in the
levels of the CDK inhibitor p27 (Donati et al., 2012). For ACC
it is not known whether p21 activation occurs independently
of p53, or even whether p21 activation contributes to the
manifestation of the skin defects.
Histological analyses of ACC wounds at birth show most
commonly a localized absence of the epidermis, whereas the
underlying dermis is usually present. Thus, although BMS1 is
ubiquitously expressed and consequences of the BMS1 muta-
tion on cell proliferation rate can be determined for example
also in skin fibroblasts in cell culture experiments, the primary
defect that results in the developmental ACC skin wounds
seems to be a consequence of a reduced cell proliferation rate
and/or reduced differentiation ability of scalp keratinocytes.
Notably, ACC patients do not have a generalized skin defect,
and the skin in other parts of the body develops normally. This
is consistent with a gene mutation that is not in a gene
encoding a structural component of the epidermis or which is
essential for skin homeostasis, but rather in a gene that affects
cell proliferation or differentiation. This may also explain why
ACC is usually limited to the vertex scalp skin: during early
embryonic development there is a rapid expansion of the
brain structures causing a high demand on the developing
scalp epidermis to proliferate, and there may be a dispropor-
tionate growth requirement for the newly forming epidermis at
the vertex area while the remaining body grows more slowly.
Scalp keratinocytes undergo massive proliferation to cover the
rapidly expanding embryonic head. Thus, it is conceivable
that a moderate impairment of proliferation capacity leads to
an inability of keratinocytes to fully form the embryonic skin at
the scalp vertex.
While the hypothesis of a high proliferative demand on
scalp keratinocytes during embryonic development is likely
part of the reason why ACC forms at the vertex area of the
scalp, there are likely additional factors that make particularly
keratinocytes more susceptible to develop defects as a
Table 1. Summary of identified genes in ACC and syndromes with ACC
ACC/syndrome
(OMIM#)
Inheritance
mode Gene Gene function Clinical characteristics Publication
Familial ACC (107600) Autosomal
dominant
BMS1 Ribosome biogenesis defect;
p21 activation
Scalp ACC Marneros, 2013,
PLoS Genetics
SEN syndrome (181270) Autosomal
dominant
KCTD1 Transcriptional repressor of AP2a ACC of scalp, lack of nipples
or breasts, variable anomalies
of digits, ears, and nails
Marneros et al., 2013,
Am J Hum Genet
AOS-1 (100300) Autosomal
dominant
ARHGAP31 Cdc42/Rac1 regulatory protein ACC of scalp, terminal
transverse limb defects
Southgate et al., 2011,
Am J Hum Genet
AOS-2 (614219) Autosomal
recessive
DOCK6 Atypical guanidine exchange
factor (GEF) activating
Cdc42 and Rac1
ACC of scalp, terminal
transverse limb defects
Shaheen et al., 2011,
Am J Hum Genet
AOS-3 (614814) Autosomal
dominant
RBPJ Primary transcriptional regulator
for the Notch pathway
ACC of scalp, terminal
transverse limb defects
Hassed et al., 2012,
Am J Hum Genet
AOS-4 (615297) Autosomal
recessive
EOGT O-GlcNAcylation of extracellular
EGF-domain-containing proteins;
Notch pathway
ACC of scalp, terminal
transverse limb defects
Shaheen et al., 2013,
Am J Hum Genet
AOS-5 Autosomal
dominant or
de novo
NOTCH1 Notch pathway ACC of scalp, terminal
transverse limb defects
Stittrich et al., 2014,
Am J Hum Genet
Abbreviations: ACC, aplasia cutis congenita; EGF, epidermal growth factor.
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consequence of the BMS1 mutation and the resultant p21
activation when compared with other cell types. It could be
hypothesized that scalp vertex epidermis defects occur in ACC
not only because of the high proliferative demand on these
keratinocytes during development, but also as a consequence
of a direct inhibitory effect of the increased p21 levels on
keratinocyte differentiation. Persistently elevated p21 expres-
sion has been shown to suppress late stages of keratinocyte
differentiation independently of its effect on the cell cycle by
keratinocyte-specific induction of IGF-1 and downstream
activation of mitogen-activated protein kinase family members
(Devgan et al., 2006). Thus, p21 needs to be downregulated
in a negative regulatory mechanism for keratinocyte
differentiation to proceed. Importantly, the p21-induced
activation of mitogen-activated protein kinases that results in
an inhibition of keratinocyte differentiation was not observed
in dermal fibroblasts. These findings suggest that p21
activation may explain a potentialy keratinocyte-specific
defect in ACC, as p21 activation may impair to some degree
cell proliferation in all cells but inhibit differentiation
particularly in keratinocytes. Furthermore, p21 restricts the
number of keratinocyte stem cell populations (Topley et al.,
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Figure 1. Representative defects in familial aplasia cutis congenita (ACC), scalp-ear-nipple syndrome (SEN), and Adams–Oliver syndrome (AOS).
(a) Affected family members in a family with autosomal-dominant ACC with a mutation in BMS1 (from Marneros, 2013). Left: 1-year-old affected boy developed
a hypertrophic scar that formed at the site of a large scalp skin defect at birth that affected the vertex and occipital scalp. Middle: father of affected boy
shows a smaller area of ACC that healed with a flat scar. Right: sister of boy shown in left image at day 1 after birth has only a small ACC lesion on her vertex scalp.
(b) Representative scalp skin defects in SEN syndrome (from Marneros et al., 2013). Scalp skin defects (left) heal with either a flat scar (middle) or with
a hypertrophic scar (right), similar as seen in familial ACC. (c) Individuals with SEN syndrome can also show syndactyly (left) and an absence of nipples
(middle and right) (from Marneros et al., 2013). (d) Congenital abnormalities in a family with AOS include aplasia cutis (left and middle) and terminal transverse
limb defects (right) (from Stittrich et al., 2014). Left: image shows a scalp defect in proband shortly after birth. Middle: scalp defect healed with a scar in the
father of proband. Right: toe abnormalities of an individual with a scalp defect shown in the middle image.
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1999; Devgan et al., 2006). It has been shown that p21
activation inhibits the transcription of genes specifically in
keratinocytes that are involved in the control of the epidermal
stem cell potential, such as Wnt4 that leads to down-
modulation of b-catenin (Devgan et al., 2005) (an increase
in Wnt/b-cateninin signaling is associated with maintenance
of keratinocytes in their stem cell compartment) (Zhu and
Watt, 1999). Thus, it could be hypothesized that p21 activa-
tion occurs as a consequence of the BMS1 mutation–induced
nucleolar stress response, and that the ACC scalp vertex
epidermis defects are a consequence of a p21-mediated
reduced cell proliferation capacity that impairs scalp kerati-
nocytes to be able to fully form the scalp epidermis during the
rapid expansion of the embryonic skull, paired with a p21-
mediated impaired keratinocyte differentiation ability and/or
reduced epidermal stem cell potential.
As dermal fibroblasts contribute through inductive signals to
the formation of the embryonic epidermis as well, it is also
possible that abnormalities of these fibroblasts due to the
BMS1 mutation may contribute to the epidermis defect to
some degree (Sil et al., 2004). Alternatively, it is possible that
the BMS1 mutation leads to ACC by affecting pathways that
regulate developmental patterning of craniofacial structures
independently of p21 activation.
SCALP-EAR-NIPPLE SYNDROME (SEN SYNDROME)
SEN syndrome is a rare autosomal-dominant disorder that
manifests with congenital aplasia cutis of the scalp and several
additional ectodermal defects, such as an absence of nipples
or breasts, ear abnormalities, and nail or digit defects (Finlay
and Marks, 1978) (Figure 1b and c). These abnormalities
strongly suggest that a novel regulator of ectodermal devel-
opment may be mutated in this syndrome. Clinically, the skin
defects manifest most commonly on the scalp and heal with a
scar, as is seen in patients with familial ACC (Figure 1b). This
phenotypic overlap suggests that SEN syndrome and ACC
share common pathomechanisms regarding the skin formation
defect affecting the scalp, whereas the gene affected in SEN
syndrome has additional functions for the proper formation of
other ectodermal structures, for whose development an
attenuated BMS1 function is not critical.
SEN syndrome manifests with ACC and is caused by mutations in
KCTD1
Missense mutations in the gene potassium-channel tetramer-
ization-domain-containing 1 (KCTD1) were identified in all 10
SEN syndrome families that were screened (Marneros et al.,
2013). KCTD1 inhibits the transactivation of AP-2 transcrip-
tion factors via a highly conserved bric-a-brac, tram track,
and broad complex domain, a so-called BTB domain, and
all of the mutations in SEN syndrome occurred in this
BTB domain of KCTD1 that is required for its transcrip-
tional repressor activity (Ding et al., 2009; Marneros et al.,
2013). Notably, mutations in the gene for AP-2a have
been identified in individuals with the branchiooculofacial
(BOF) syndrome, which presents with branchial aplasia cutis
(Milunsky et al., 2008). This overlap of aplasia cutis in BOF
syndrome and SEN syndrome suggests that mutations in
KCTD1 likely cause congenital skin formation defects
through their effects on the developmentally regulated
transcription factor AP-2a, which has been implicated in
terminal differentiation of various tissues during embryo-
genesis (Schorle et al., 1996; Zhang et al., 1996).
Hypotheses of how KCTD1 missense mutations may lead to SEN
syndrome
Through which molecular mechanisms KCTD1 mutations lead
to the observed ectodermal defects and particularly aplasia
cutis is not known at present. It is also not known whether
these mutations in KCTD1 represent loss- or gain-of-function
mutations. It remains to be determined whether autosomal-
dominant ACC and SEN syndrome share common down-
stream molecular pathways that explain the phenotypic
overlap of the scalp skin defects. Notably, AP-2a has been
shown to induce expression of p21 (Zeng et al., 1997; Scibetta
et al., 2010). Thus, loss-of-function mutations in KCTD1 in
SEN syndrome would be predicted to enhance AP-2a activity
and result in p21 activation during development. Therefore, it
could be hypothesized that the skin morphogenesis defects
observed in ACC due to the BMS1 mutation and in
SEN syndrome due to the KCTD1 mutations may at least in
part occur because of p21 activation, which may synergize
with other altered pathways to interfere with proper skin
development.
AP-2 transcription factors are strongly expressed in the basal
and suprabasal layer of the epidermis and also in hair follicles
and dermal papillae, bind to many epidermally expressed
genes, and have been suggested to have an important role in
the switch between epidermal cell proliferation and differ-
entiation (Wang et al., 2006; Wang et al., 2008). AP-2a and
AP-2g show functional redundancies in the epidermis, but
ablation of both AP-2a and AP-2g in the epidermis resulted in
severe defects of epidermal terminal differentiation, in part by
repressing C/EBP transcription factors (Wang et al., 2008).
Notably, KCTD1 can repress all three AP-2 family members
(AP-2a, AP-2b, and AP-2g) (Ding et al., 2009), raising the
possibility that mutations in KCTD1 in SEN syndrome patients
may affect epidermal differentiation through effects on both
AP-2a and AP-2g activities that may contribute to ACC skin
defects. Notably, mice with epidermal deletion of both AP-2a
and AP-2g resembled skin defects seen in mice with epidermal
inactivation of the Notch transcriptional regulator RBP/J, and it
has been suggested that AP-2 transcription factors synergize
with the canonical Notch pathway to regulate C/EBP
transcription factors that contribute to the differentiation of
basal epidermal cells to spinous keratinocytes (Blanpain et al.,
2006; Wang et al., 2008). Thus, it is possible that the ACC
defects in SEN syndrome patients may result from a
combination of (1) abnormal epidermal differentiation
through altered function of AP-2 transcription factors, and
(2) through epidermal cell proliferation and differentiation
defects as a consequence of altered p21 levels.
ADAMS-OLIVER SYNDROME (AOS)
AOS is a genetically highly heterogenous heterogeneous
syndrome, which manifests with the main features of
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congenital ACC of the scalp and terminal transverse limb
defects (Figure 1d). Particularly the extent of the limb defects
has been described to vary widely among affected individuals
(Kuster et al., 1988). Less commonly cardiac and vascular
abnormalities have been associated with AOS syndrome. AOS
syndrome may occur in families with an autosomal-dominant
or autosomal-recessive inheritance pattern, or it may occur
sporadically without a family history.
Mutations in EOGT, NOTCH1, and in RBP/J in a subset of AOS:
a role for altered Notch signaling in AOS
In a subset of families with autosomal-recessive AOS, muta-
tions in the gene EOGT (endoplasmic reticulum-resident
O-GlcNAc transferase) were identified, which encodes the
epidermal growth factor-domain-specific O-linked N-acetylglu-
coasmine (O-GlcNAc) transferase (Shaheen et al., 2013; Cohen
et al., 2014). EOGT expression during development assumed a
digit-condensation pattern in the four limbs and was also
observed in craniofacial structures at E12.5, correlating with
the location of the abnormalities in AOS (Shaheen et al.,
2013). EOGT functions in O-GlcNAcylation (attachment of O-
GlcNAc to serine and threonine residues) of extracellular
epidermal growth factor domains of membrane proteins and
resides in the endoplasmic reticulum within the secretory
pathway. Loss of EOGT in Drosophila results in phenotypes
attributed to defective cell–matrix interactions (Sakaidani
et al., 2011). A mass spectrometry study identified O-
GlcNAcylation of extracellular epidermal growth factor-like
domains of a number of proteins, including Notch2, Lama5,
and Hspg2 (Alfaro et al., 2012). This study suggested a role of
EOGT in the post-translational modification of various
proteins involved in the Notch signaling pathway and in
extracellular matrix–receptor interactions. Notably, EOGT has
previously been shown to attach O-b-GlcNAc to Notch
receptors in Drosophila and in mice (Matsuura et al., 2008;
Sakaidani et al., 2012). In addition, O-GlcNAc modification
through EOGT was also found on Delta and Serrate, ligands
for Notch receptors (Matsuura et al., 2008; Muller et al.,
2013). Moreover, the recent identification of heterozygous
mutations in the RBP/J gene (the primary transcriptional
regulator of the Notch signaling pathway) and in NOTCH1
in a subset of individuals with AOS has provided further
evidence for a role of the Notch pathway in AOS pathogenesis
(Hassed et al., 2012; Stittrich et al., 2014). Mutations in RBP/J
in individuals with AOS were shown to affect the DNA-
binding ability of RBP/J to the HES1 promoter (a RBP/J-
dependent Notch target gene) and to result in decreased
HES1 expression (Hassed et al., 2012). Consistent with the
aplasia cutis and limb abnormalities in AOS patients with RBP/
J mutations, it has been demonstrated that RBP/J-mediated
Notch-signaling has important roles for mesenchymal progeni-
tor cell differentiation and proliferation during skeletal
development and for hair follicle and skin development
(Vauclair et al., 2005; Blanpain et al., 2006; Dong et al.,
2010). Importantly, it has been shown that RBP/J and Notch
have critical roles in terminal differentiation of keratinocytes
and that spinous layer gene induction is mediated by a Hes1-
mediated mechanism (Blanpain et al., 2006).
These findings suggest a possible common pathomechanism
that leads to the skin defects seen in SEN syndrome and AOS,
as AP-2 transcription factors (affected by KCTD1 mutations in
SEN syndrome) and Notch signaling (affected by EOGT, RBP/J,
or NOTCH1 mutations in AOS) have been shown to synergize
in epidermal differentiation by regulating C/EBP transcription
factors (Wang et al., 2008).
Mutations in genes that regulate the Rho family members Cdc42
and Rac1 in AOS
A recent study identified gain-of-function mutations in the
ARHGAP31 gene in two kindreds with autosomal-dominant
AOS (Southgate et al., 2011). The ARHGAP31 gene is a
member of the RhoGAP protein family and has been shown
to inactivate the Rho GTPases Cdc42 and Rac1 (through
hydrolysis of GTP to guanosine diphosphate), which are
involved in a large number of cellular functions, including
cell proliferation, cell migration, and cytoskeletal dynamics.
The localized abnormalities of the scalp skin and the terminal
limbs as a consequence of the ARHGAP31 mutations in AOS
may be explained by the restrictive expression pattern of
ARHGAP31 during development that is observed particularly
in the terminal limb buds and craniofacial processes
(Southgate et al., 2011). These ARHGAP31 mutations result
in a reduction in active available Cdc42 and may through this
mechanism affect actin cytoskeletal structures (Southgate et al.,
2011). Consistent with this hypothesis, it has been shown that
ARHGAP31 functions as a regulator of integrin-induced Rho
family signaling to the cytoskeleton (LaLonde et al., 2006).
Cdc42 and Rac1 have important roles for skin morphogen-
esis, which may explain the scalp skin defects in individuals
with AOS who carry mutations in ARHGAP31. Inactivation of
Cdc42 in keratinocytes increased degradation of b-catenin
(which was dependent on PKCz), and impaired the differentia-
tion of skin progenitor cells to the hair follicle lineage (Wu
et al., 2006). On the basis of these findings it has been
speculated that a gain-of-function ARHGAP31 mutation
would lead to reduced active cellular GTP-Cdc42 levels,
which subsequently would result in decreased active PKCz
and a concomitant increase in b-catenin degradation (Southgate
et al., 2011). Similarly, an important role of Rac1 for hair
follicle development has been reported (Benitah et al., 2005;
Chrostek et al., 2006). Moreover, Rac1 regulates keratinocyte
migration and proliferation and its inhibition impairs epidermal
wound healing (Tscharntke et al., 2007). Conditional inactiva-
tion of Rac1 in both the limb bud ectoderm or mesenchyme
resulted in developmental limb abnormalities (Suzuki et al.,
2009). Thus, the results from genetic mouse studies targeting
Cdc42 or Rac1 in a tissue-specific manner are consistent with
the clinical manifestations in individuals with AOS who carry
activating mutations in ARHGAP31 and that affect the levels of
active Cdc42 and Rac1.
Further genetic evidence for a role of Cdc42 and Rac1
activity in AOS pathogenesis has been provided by the identi-
fication of homozygous truncating mutations in the DOCK6
gene in autosomal-recessive AOS (Shaheen et al., 2011).
DOCK6 encodes an atypical guanidine exchange factor that
activates Cdc42 and Rac1 (stimulates replacement of
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guanosine diphosphate to GTP). Thus, inactivating mutations
in DOCK6 or gain-of-function mutations in ARHGAP31
would be predicted to reduce active levels of Cdc42 or
Rac1 and affect diverse cellular functions.
Notably, some of the individuals affected with AOS who
carry mutations in either DOCK6, EOGT, or NOTCH1 have
been reported to have additional cardiac or vascular devel-
opmental abnormalities (including cardiac septal defects,
pulmonary vascular defects, cutis marmorata, and brain
infarcts). These findings have led to the hypothesis that
mutations in these genes affect developmental angiogenesis
and that even the observed aplasia cutis and bony skull and
digit abnormalities may to some degree also be a consequence
of abnormal blood vessel development (Stittrich et al., 2014).
This hypothesis is intriguing and requires further exploration,
given the well-known role of Notch signaling in blood vessel
morphogenesis and vascular smooth muscle cell differentia-
tion (Anderson and Gibbons, 2007).
SUMMARY
Recent genetic studies have revealed novel genes and path-
ways that when altered result in aplasia cutis of the scalp and
suggest critical roles of these genes for skin morphogenesis.
Why particularly the scalp skin is affected is not known, but it
can be hypothesized that the rapid expansion of the skull
during development requires a disproportionate proliferation
and/or differentiation rate of skin cells at that site and
predisposes the scalp to congenital skin defects, or alterna-
tively that developmental patterning defects affect particularly
the scalp skin through distinct mechanisms. These genetic
studies suggest that particularly (1) ribosomal stress and p21
activation, (2) altered functions of AP-2 transcription factors
and Notch signaling, and (3) abnormal activity of Cdc42 and
Rac1, may represent common pathomechanisms that lead to
the observed skin defects. In conclusion, the recent discoveries
of ACC-causing gene mutations suggest that multiple genes
and distinct signaling pathways may converge to regulate skin
morphogenesis of the scalp and that mutations affecting
different cellular pathways may result in overlapping and very
similar congenital skin defects. Future genetic mouse models
of these inherited conditions will be instrumental to elucidate
whether the mutated genes lead to skin defects through shared
common downstream cellular pathomechanisms.
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